Made With Uberflip Content Marketing

Pharmacy and Research

From biosimilars to precision medicine to drug costs, here’s your ultimate guide to all things pharmacy and research.

  • Premier Healthcare Database Whitepaper

    Premier Healthcare Database Whitepaper

    Premier Healthcare Database has been utilized by the pharmaceutical and device industries, academia, healthcare insurers and healthcare policy makers for clinical, financial and outcomes analyses.

    Open File
  • A Look Forward To Healthcare In 2017: Top Five Trends

    A Look Forward To Healthcare In 2017: Top Five Trends

    Premier’s Susan DeVore discusses healthcare industry trends to expect this year, including the repeal/replacement of the Affordable Care Act, the growth and acceleration of value-based care and more.

    Read Article
  • ×

    Want to Learn More About How Premier Can Help You?

    First Name
    Last Name
    Phone Number
    Organization
    Thank you! You'll Hear From Us ASAP.
    Error - something went wrong!
  • Biosimilars 101: Facts, Risks & Opportunities

    Biosimilars 101: Facts, Risks & Opportunities

    The emergence of biosimilars over the last few years has introduced a new competitive specialty pharmaceuticals market to combat the rising price tags on expensive biologics.

    Open File
  • Rethink: Healthcare in 2017

    Rethink: Healthcare in 2017

    Here are three focus areas for the Trump Administration that will help capitalize on the healthcare gains we’ve already achieved.

    Read Article
  • Biosimilars: A Tipping Point

    Biosimilars: A Tipping Point

    With biosimilars, the U.S. healthcare industry has a remarkable opportunity to make lifesaving and disease-altering drugs more accessible and more affordable. Read more.

    Open File
  • What Are Biosimilars?1:11

    What Are Biosimilars?

    Watch to learn more.

    Watch Video
  • Economic Outlook: Fall 2016 C-Suite Survey

    Economic Outlook: Fall 2016 C-Suite Survey

    The fall 2016 Economic Outlook survey polled 52 health system C-suite executives from across the U.S. on some of the biggest issues facing health systems as a whole.

    Open File
  • 3 Action Items to Thrive in Value-Based Care

    3 Action Items to Thrive in Value-Based Care

    While we wait for the dust to settle from the presidential election, there is much uncertainty. However, we believe the movement away from pay-for-volume to pay-for-value will continue. Read more.

    Read Article
  • Real-World Evidence: From Volume to Value

    Real-World Evidence: From Volume to Value

    Read Article
  • Faster FDA Approvals of New Drugs Would Lead to Lower Prices, Says Premier CEO

    Faster FDA Approvals of New Drugs Would Lead to Lower Prices, Says Premier CEO

    Susan DeVore, CEO of healthcare company Premier, says increased competition is needed to reduce prescription drug costs.

    Read Article
  • Coalition Says Transparency, Value-based Pay Could Contain Drug Costs

    Coalition Says Transparency, Value-based Pay Could Contain Drug Costs

    Increased transparency and competition in the pharmaceutical industry and expanded value-based payment models would help address rising prescription drug prices, according to a coalition aimed at ...

    Read Article
  • Unpacking Drug Price Spikes: Generics

    Unpacking Drug Price Spikes: Generics

    The generic medication market has been in turmoil—shortages, price spikes, quality issues, compounding abuse—since 2008.

    Read Article
  • Three Ways Providers Should Address Drug Shortages

    Three Ways Providers Should Address Drug Shortages

    Preventing drug shortages requires a “swat team” mentality by all, including FDA, manufacturers, group purchasing organizations (GPOs), and health systems.

    Read Article
  • Specialty Pharmacy: Not for the Faint of Heart

    Specialty Pharmacy: Not for the Faint of Heart

    Strategic use of specialty drugs can cure complex, chronic conditions in some cases, or dramatically reduce their medical costs in others.

    Read Article
  • How Competition Can Bring Down Drug Prices

    How Competition Can Bring Down Drug Prices

    Premier chief executive officer, Susan DeVore, discusses today's high drug prices and shares her thoughts on how competition might be able to drive costs down.

    Read Article
  • Taking Action Against Drug Shortages

    Taking Action Against Drug Shortages

    Although the severity of drug shortages has eased somewhat in recent years, providers still are frequently unable to offer patients the medications they need.

    Read Article
  • Who's Teaching Whom Biosimilars? The Rise of Patient Education

    Who's Teaching Whom Biosimilars? The Rise of Patient Education

    As consumers begin to adapt to the high cost of biologic medicines and their biosimilar counterparts, there may be a shift in education, with patients – not providers – leading the way.

    Read Article
  • Specialty Pharmacy: Not for the Faint of Heart

    Specialty Pharmacy: Not for the Faint of Heart

    According to the CDC, chronic diseases—such as heart disease, stroke, cancer, type 2 diabetes, obesity and arthritis—are among the most common, costly, and preventable of all health problems.  

    Read Article
  • Biosimilars' Success in the US: Will Physicians Rule the Road?

    Biosimilars' Success in the US: Will Physicians Rule the Road?

    Payers are anxiously anticipating the introduction of biosimilar medicines in the US.

    Read Article
  • Five Purchasing Trends Driving Significant Cost Reductions in Healthcare

    Five Purchasing Trends Driving Significant Cost Reductions in Healthcare

    Premier chief operating officer, Mike Alkire, shares five purchasing trends that are driving significant cost reductions in healthcare.

    Read Article
  • loading
    Loading More...